MoneyWorks4Me

Ajanta Pharma informs about disclosure of material impact of COVID-19

11 Jun 2020 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. SEBI/HO/CFD/CMDl/CIR/P/2020/84 dated 20th May 2020, Ajanta Pharma has informed that it has enclosed the disclosure of material impact of COVID 19 pandemic on listed companies.

The above information is a part of company’s filings submitted to BSE.


Peers
Company Name CMP
Sun Pharma. Inds. 1783.25
Dr. Reddys Labs. 1202.40
Cipla 1329.50
Lupin 2007.10
Zydus Lifesciences 1154.00
View more..